Idec pulls the plug on Specifid

Poised to begin Phase II and III studies of its Specifid panel of 15 antibodies for B-cell lymphoma, Idec Pharmaceuticals Corp. instead has decided to drop Specifid in favor of its single-antibody pan-B products. The decision was based on a combination of manufacturing issues and return on investment calculations.